Southern California Research Center, Coronado, California, USA.
Mayo Clinic, Jacksonville, Florida, USA.
Aliment Pharmacol Ther. 2024 Jul;60(2):246-256. doi: 10.1111/apt.18054. Epub 2024 May 22.
The quantitative HepQuant SHUNT test of liver function and physiology generates a disease severity index (DSI) that correlates with risk for clinical complications, such as large oesophageal varices (LEVs). A derivative test, HepQuant DuO, generates an equivalent DSI and simplifies testing by requiring only oral administration of the test solution and two blood samples at 20 and 60 min.
Since the DSIs measured from DuO and SHUNT are equivalent, we compared the diagnostic performance for large oesophageal varices (LEVs) between the DSIs measured from DuO and SHUNT tests.
This study combined the data from two prospectively conducted US studies: HALT-C and SHUNT-V. A total of 455 subjects underwent both the SHUNT test and esophagogastroduodenoscopy (EGD).
DSI scores correlated with the probability of LEVs (p < 0.001) and demonstrated a stepwise increase from healthy lean controls without liver disease to subjects with chronic liver disease and no, small or large varices. Furthermore, a cutoff of DSI ≤ 18.3 from DuO had a sensitivity of 0.98 (missing only one case) and, if applied to the endoscopy (EGD) decision, would have prevented 188 EGDs (41.3%). The AUROC for DSI from DuO did not differ from that of the reference SHUNT test method (0.82 versus 0.81, p = 0.3500).
DSI from HepQuant DuO links liver function and physiology to the risk of LEVs across a wide spectrum of patient characteristics, disease aetiologies and liver disease severity. DuO is minimally invasive, easy to administer, quantitative and may aid the decision to avoid or perform EGD for LEVs.
肝定量 HepQuant SHUNT 肝功能和生理学测试生成疾病严重程度指数(DSI),与临床并发症(如大食管静脉曲张(LEVs))的风险相关。衍生测试 HepQuant DuO 通过仅要求口服测试溶液和 20 分钟和 60 分钟时的两份血液样本,生成等效的 DSI 并简化测试。
由于 DuO 和 SHUNT 测量的 DSI 是等效的,我们比较了 DuO 和 SHUNT 测试测量的 DSI 对大食管静脉曲张(LEVs)的诊断性能。
本研究结合了两项前瞻性美国研究(HALT-C 和 SHUNT-V)的数据。共有 455 名受试者接受了 SHUNT 测试和食管胃十二指肠镜检查(EGD)。
DSI 评分与 LEVs 的概率相关(p<0.001),并且从没有肝脏疾病的健康瘦对照者到患有慢性肝脏疾病且没有、小或大静脉曲张的患者,DSI 呈逐步增加。此外,DuO 的 DSI≤18.3 的截断值具有 0.98 的敏感性(仅漏诊一个病例),如果应用于内镜(EGD)决策,将可避免 188 例 EGD(41.3%)。DuO 来自 DSI 的 AUROC 与参考 SHUNT 测试方法没有差异(0.82 对 0.81,p=0.3500)。
HepQuant DuO 的 DSI 将肝功能和生理学与 LEVs 的风险联系起来,跨越了广泛的患者特征、病因和肝脏疾病严重程度。DuO 是微创、易于管理、定量的,可能有助于决定是否避免或进行 LEVs 的 EGD。